Clinical trials
Marginal Zone Lymphoma clinical trials
Below are recruiting marginal zone lymphoma clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT03869619Recruiting
Real-life data study for adults with recent lymphoma
This study collects “real-world” health information about adults whose lymphoma was diagnosed within the last 6 months. It aims to better understand lymphoma types and how patients do over time, using data from everyday care rather than testing a new drug.
ArrasAges 18 years+ - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT06454968RecruitingPhase 2
Combination therapy for first-line marginal zone lymphoma
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06503276RecruitingPhase 2
Orelabrutinib and radiation for a type of eye lymphoma
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06513234RecruitingPhase 2
Orelabrutinib and Obinutuzumab for untreated marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
TianjinAges 18 years+ - NCT06478472Recruiting
Orelabrutinib plus rituximab for marginal zone lymphoma
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Xiamen, FujianAges 18 years+ - NCT06566807RecruitingPhase 2
Orelabrutinib plus obinutuzumab for marginal zone lymphoma
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
Huai'an, JiangsuAges 18 years+ - NCT07763210RecruitingPhase 2
IT therapy for immune cell-related side effects after CAR T
This trial tests a new way to give treatment directly into the spinal fluid for a serious side effect of CAR T cell therapy called ICANS. It may help people with certain types of lymphoma who are getting standard CAR T therapy and experience this brain-related complication.
Nashville, TennesseeAges 18 years+ - NCT06592170RecruitingPhase 1/Phase 2
Linperlisib and obinutuzumab for new MZL
This trial tests a combination of two drugs for people newly diagnosed with marginal zone lymphoma (MZL). The goal is to see if the combination works better than standard treatments.
Changchun, JilinAges 18 years+ - NCT04834024RecruitingPhase 3
MIL62 plus lenalidomide vs lenalidomide alone for rituximab-refractory lymphoma
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
BeijingAges 18 years+ - NCT04110301RecruitingPhase 1/Phase 2
MIL62 plus lenalidomide for relapsed follicular or MZ lymphoma
This early-stage study tests whether MIL62 combined with lenalidomide can shrink or control follicular lymphoma or marginal zone (MZ) lymphoma that has come back or not responded to earlier treatment. It’s designed for adults with measurable disease and enough body strength to take part.
BeijingAges 18 years+ - NCT06534463Recruiting
MZL patient registry study
This study is a registry that collects information on Chinese patients with marginal zone lymphoma. It helps doctors learn more about how MZL behaves and how it is treated.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT07583810RecruitingPhase 2
Nemtabrutinib and Rituximab for Marginal Zone Lymphoma
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06806488Recruiting
Marginal zone lymphoma patient study
This study looks at patients with marginal zone lymphoma who were diagnosed and treated at a specific hospital in Italy between 2012 and 2018. It aims to learn more about how the disease progresses and how patients respond to treatment.
Bologna, BolognaAges 18 years+ - NCT06823960Recruiting
Zanubrutinib for marginal zone lymphoma in Italy
This study checks how well and how safely zanubrutinib worked for people with marginal zone lymphoma who got the drug through a special access program in Italy. The goal is to learn more about the drug's real-world effects and help future patients.
Alessandria, AlessandriaAges 18 years+ - NCT07355699RecruitingPhase 4
Orelabrutinib for untreated marginal zone lymphoma
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
BeijingAges 18 years+ - NCT07233720Recruiting
Zanubrutinib plus rituximab for first-line marginal zone lymphoma
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
Zhengzhou, HenanAges Any age - NCT07225439RecruitingPhase 1
Rituximab and tafasitamab with donor immune cells for lymphoma
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
Cleveland, OhioAges 18 years+ - NCT07173790Enrolling by invitation
Watch and Wait in Slow-Growing Lymphoma
This study looks at how people with slow-growing lymphomas (like CLL, MZL, FL, or WM) feel during watchful waiting — when they are not on active treatment. It aims to see if patients are more anxious or worried, and how to best support them.
Seoul, Gangnam-guAges 19 years+ - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Marginal Zone Lymphoma trials by city
Studies with a site in or near these metro areas.
Marginal Zone Lymphoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for marginal zone lymphoma?
- Yes. Clin2 currently lists 86 recruiting marginal zone lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a marginal zone lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a marginal zone lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.